Logo Ecole Polytechnique Logo ESPCI
Logo UPS Logo UDL
Logo Sorbonne Universite Logo Universite de Lille 1
Logo Rouen Logo INSA Rouen Normandie

Accueil du site > Production scientifique > Proteomics applied to transfusion plasma : the beginning of the story

Proteomics applied to transfusion plasma : the beginning of the story

Date de publication: 26 février 2013

A. Ortiz, L. Richa, C. Defer, D. Dernis, J.-J. Huart, C. Tokarski, C. Rolando
Vox Sanguinis 104 275–291 (2013). DOI

Travail réalisé sur le site de l’Université de Lille 1, Sciences et Technologies.


‘Safe blood’ is and has always been the major concern in transfusion medicine. Plasma can undergo virus inactivation treatments based on physicochemical, photochemical or thermal methodologies for pathogen inactivation. The validation of these treatments is essentially based on clottability assays and clotting factors’ titration ; however, their impact on plasma proteins at the molecular level has not yet been evaluated. Proteomics appears as particularly adapted to identify, to localize and, consequently, to correlate these modifications to the biological activity change. At the crossroads of biology and analytical sciences, proteomics is the large-scale study of proteins in tissues, physiological fluids or cells at a given moment and in a precise environment. The proteomic strategy is based on a set of methodologies involving separative techniques like mono- and bidimensional gel electrophoresis and chromatography, analytical techniques, especially mass spectrometry, and bioinformatics. Even if plasma has been extensively studied since the very beginning of proteomics, its application to transfusion medicine has just begun. In the first part of this review, we present the principles of proteomics analysis. Then, we propose a state of the art of proteomics applied to plasma analysis. Finally, the use of proteomics for the evaluation of the impact of storage conditions and pathogen inactivation treatments applied to transfusion plasma and for the evaluation of therapeutic protein fractionated is discussed.